Results 161 to 170 of about 22,544,156 (338)

A Delphi consensus project to capture experts' opinion on hyperkalaemia management across the cardiorenal spectrum

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1132-1140, April 2025.
Abstract The main purpose of this project was to capture experts' opinion on hyperkalaemia management and form best practice recommendations for cardiorenal patients in Greece. A steering committee of nephrologists and cardiologists developed 37 statements. An online questionnaire completed by 32 experts in cardiorenal management in Greece.
Christina Chrysohoou   +3 more
wiley   +1 more source

Early in‐hospital treatment of acute heart failure. Part 2 of the international expert opinion series on AHF management

open access: yesESC Heart Failure, EarlyView.
This state‐of‐the‐art review outlines a practical, evidence‐based framework for early acute heart failure management to address critical gaps in current guidance and improve early treatment outcomes. Key components include early identification of co‐existing conditions, bedside haemodynamic profiling, a structured diagnostic approach incorporating both
Anika S. Naidu   +22 more
wiley   +1 more source

The evolving role of the renin–angiotensin system in ARDS [PDF]

open access: gold, 2017
Eleni Vrigκou   +4 more
openalex   +1 more source

Digital implementation strategy to increase SGLT2 inhibitor uptake in heart failure: Study design of EMAIL‐HF

open access: yesESC Heart Failure, EarlyView.
Abstract Aims The EMAIL‐HF trial aims to evaluate whether a digital guideline implementation strategy can increase and accelerate initiation of sodium‐glucose co‐transporter 2 (SGLT2) inhibitors in patients with heart failure (HF). Methods and results EMAIL‐HF is a pragmatic, registry‐based, randomized controlled trial including patients with a ...
Mariam Elmegaard   +21 more
wiley   +1 more source

Phenotype characterization of heart failure with preserved ejection fraction in medical device and surgical trials

open access: yesESC Heart Failure, EarlyView.
This systematic review identified 24 clinical trials of medical device and surgical interventions for HFpEF, with 16 demonstrating at least safety and feasibility, but little evidence of long‐term benefit. Phenotype‐based responses suggest that certain interventions may benefit specific HFpEF subgroups, yet most trials suffered from heterogeneous ...
Kurdo Araz   +5 more
wiley   +1 more source

Epidemiology, pathophysiology, diagnosis and management of atrial functional mitral regurgitation: An expert opinion paper

open access: yesESC Heart Failure, EarlyView.
The graphical abstract summarizes the key features of AFMR in terms of epidemiology, pathophysiology, diagnosis, medical therapy and rhythm control, surgical and transcatheter interventions, and future directions. Created in BioRender (https://BioRender.com/3zj03ko).
Matteo Pagnesi   +14 more
wiley   +1 more source

An In-Depth Examination of Formularies and Other Features of Medicare Drug Plans [PDF]

open access: yes, 2006
Provides a detailed assessment of the formularies, drug costs, and utilization management tools offered by the fourteen nationwide organizations that account for most of the stand-alone prescription drug ...
Elizabeth Hargrave   +3 more
core  

The emerging role of Nrf2 in heart failure: From cardioprotection to therapeutic approaches

open access: yesESC Heart Failure, EarlyView.
Nrf2 signalling is impaired in heart failure, contributing to oxidative stress, mitochondrial dysfunction, and ferroptosis, which drive neurohormonal activation, inflammation, and ischaemia‐reperfusion injury. This loss of Nrf2 activity exacerbates hypertension, diabetic cardiomyopathy, and cardiotoxicity, accelerating progression to overt heart ...
Emiliano Fiori   +9 more
wiley   +1 more source

SGLT2 inhibitors for the prevention and treatment of heart failure: A scientific statement of the HFA and the HFAI

open access: yesESC Heart Failure, EarlyView.
Abstract In the 2021 European Society of Cardiology (ESC) heart failure (HF) guidelines, sodium–glucose cotransporter 2 (SGLT2) inhibitors were recommended for the prevention of HF in patients with type 2 diabetes mellitus (T2DM) and for the treatment of HF with reduced ejection fraction (HFrEF).
Marco Metra   +25 more
wiley   +1 more source

Home - About - Disclaimer - Privacy